Epidemiological characteristics of SARS-CoV-2 infection
Infection sources
Transmission route
Susceptible population and epidemic characteristics
Etiology and pathological mechanism
Clinical manifestations
Severe and critical clinical warning indicators [3]
Auxiliary examinations
Routine laboratory examinations [3, 11, 14]
Etiological detection
Other methods
Imaging features [11, 17, 18]
Chest X-ray examination
Chest CT scan
Diagnosis [3, 15, 19]
Suspected cases
Epidemiological history
Clinical features
Confirmed case
Differential diagnosis
Case discovery and reporting (isolation measures)
Case detection, reporting, and isolation [3, 13]
Medical observation [5, 23, 24]
Treatment
Medical isolation
General treatment
Oxygen therapy
Antiviral treatment
Antiviral drugs | Dosage | Indications | Side effects |
---|---|---|---|
Interferon α | 200,000 to 400,000 IU/kg in 2 mL sterile water, with nebulization two times per day for 5–7 days | Covid-19, chronic hepatitis B and C patients, etc. | Fever, headache, nausea, vomiting, lack of concentration, and even pessimism |
Lopinavir/litonavir | Weight 7–15 kg, 12 mg/3 mg/kg; weight 15–40 kg, 400 mg/100 mg as adult each time, twice a day for 1–2 weeks | COVID-19 and HIV patients | Diarrhea, nausea and vomiting |
Ribavirin | 10 mg/kg/time, via intravenous infusion, 2 to 3 times daily | COVID-19 patients, viral pneumonia, and bronchitis caused by respiratory syncytial virus | Teratogenic and hemolytic anemia |
Remdesivir | – | COVID-19 patients | Skin rash, diarrhea, and renal dysfunction |
Favipiravir | – | COVID-19 patients | Skeletal muscle atrophy and myocardial necrosis |
Chloroquin phosphate/Hydroxychloroquine | 3–5 mg/kg/day (max dose 400 mg) hydroxychloroquine sulfate iv, twice daily for 5 days | COVID-19 and malaria patients | QT interval prolongation, ventricular arrhythmias and other cardiac toxicity |